 |
|
||||||
| • advocacy |
TEXT SIZE
 
|
print
Advocacy - Public Policy News Releases
|
|||
|
Next up in our Patient Education Series on the Affordable Care Act: Learn the alphabet soup of private health insurance changes coming in 2014 – QHPs, EHBs, OOPs, marketplaces and more! Join us to hear from a panel of experts from think tanks and policy groups who will discuss what cancer patients and their families need to know nowabout the health insurance world in 2014. | ||
|
|||
|
|||
|
|||
|
|
|||
|
|||
|
The federal Cancer Drug Coverage Parity Act will dramatically improve the lives of cancer patients. Patients who previously could not afford these treatments will be able to access their life‐saving effects. It will also make cancer treatments more practical for patients living in rural and underserved areas by reducing the need to drive long distances for a nurse or doctor to administer treatment. | ||
|
|||
|
|
|||
|
|||
|
|
|||
|
|||
|
|
|||
|
|||
|
|
|||
|
|||
|
|
|||
|
|||
|
|
|||
|
|||
|
|
|||
|
|||
|
|
|||
|
|||
|
|
|||
|
|||
|
|
|||
|
|||
|
|
SPEAC held first meeting with cancer advocates in Springfield, Illinois to discuss how to work together to ensure Illinois' state health exchange offers affordable access to comprehensive cancer care. | ||
|
|||
|
|
This summer the IMF formed the State Patients Equal Access Coalition (SPEAC), which is a patient-focused coalition working collaboratively to ensure that cancer patients have appropriate access to a broad range of approved and medically-accepted anticancer regimens. | ||
|
|||
|
|
The IMF Advocacy Team has seen major growth this year with two new additions. We are proud to announce that because of our team growth we have been able to expand our reach to help myeloma patients around the world get access to the treatments they need. | ||
|
|||
|
|
|||
|
|||
|
|
|||
|
|||
|
|
"My role as a myeloma specialist is to treat patients with the newest, most-effective treatments," said Dr Arthur Molina, Ochsner’s Director of Bone Marrow Transplantation and Hematological Malignancies. "I am concerned when patients tell me they would rather have an older, less tolerable drug because their insurance plan will reimburse them at a higher rate." | ||
|
|||
|
|
|||
|
|||
|
|
|||
back to top